Provides clinical development services for drugs, biologics, and devices. Offers commercialization solutions to pharmaceutical and biotechnology companies. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
This is an established company with proven profits.
Average growth of 5% a year over the last 4 years. Every year shown ended in profit.
The gap is $2.8B. In times of high interest rates, a gap like that can squeeze a company.
The market pays 16.7× for every dollar of annual profit — around what a business like this usually costs.
Analysts' average target sits 68% above today's price.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Cost Efficiency: As sales grow, profit fails to keep the same pace.
The stock trades 58% below its peak. The market has trimmed its expectations for the company.
Our checks did not surface a specific strength to highlight here.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
Costs swallow the gains that sales growth brings in. Council score: 4/10.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.